Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: November 13, 2019

DrugPatentWatch Database Preview


See Plans and Pricing

« Back to Dashboard

When do Sucralfate patents expire, and when can generic versions of Sucralfate launch?

Sucralfate is a drug marketed by Mylan Ireland Ltd and Teva and is included in two NDAs.

The generic ingredient in SUCRALFATE is sucralfate. There are fourteen drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the sucralfate profile page.

Drug patent expirations by year for SUCRALFATE
Drug Prices for SUCRALFATE

See drug prices for SUCRALFATE

Drug Sales Revenue Trends for SUCRALFATE

See drug sales revenues for SUCRALFATE

Recent Clinical Trials for SUCRALFATE

Identify potential brand extensions & 505(b)(2) entrants

University of Texas at AustinPhase 2
Taipei Veterans General Hospital, TaiwanN/A
Pamukkale UniversityPhase 4

See all SUCRALFATE clinical trials

Pharmacology for SUCRALFATE
Medical Subject Heading (MeSH) Categories for SUCRALFATE

US Patents and Regulatory Information for SUCRALFATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Ireland Ltd SUCRALFATE sucralfate TABLET;ORAL 074415-001 Jun 8, 1998 DISCN No No   Start Trial   Start Trial   Start Trial
Teva SUCRALFATE sucralfate TABLET;ORAL 070848-001 Mar 29, 1996 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.